OncoCyte Corporation (OCX)

May 23, 2025

Midday Stock Roundup: GEN Restaurants Down. BJ’s Restaurants Up - Orange County Business Journal

May 23, 2025

May 23, 2025

Lake Street Capital Forecasts Strong Price Appreciation for OncoCyte (NASDAQ:OCX) Stock - Defense World

May 23, 2025

May 21, 2025

Lake Street Raises Price Target for OncoCyte (OCX) to $8.00 | OC - GuruFocus

May 21, 2025

May 21, 2025

Lake Street Raises Price Target for OncoCyte (OCX) to $8.00 | OCX Stock News - GuruFocus

May 21, 2025

May 21, 2025

Oncocyte (OCX) Gains Favorable Reimbursement for GraftAssureCore Test | OCX Stock News - GuruFocus

May 21, 2025

May 21, 2025

OncoCyte (OCX) Price Target Raised Amid Reimbursement Boost | OC - GuruFocus

May 21, 2025

May 21, 2025

OncoCyte reports Medicare boosts reimbursement for GraftAssureCore - TipRanks

May 21, 2025

May 21, 2025

OncoCyte (OCX) Price Target Raised Amid Reimbursement Boost | OCX Stock News - GuruFocus

May 21, 2025

May 21, 2025

OncoCyte price target raised to $8 from $5 at Lake Street - TipRanks

May 21, 2025

May 19, 2025

Oncocyte Corp Says New CMS Reimbursement Price Rate Of $2,753 Per Result For Graftassurecore Assay - marketscreener.com

May 19, 2025

May 19, 2025

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology - The Manila Times

May 19, 2025

May 19, 2025

Medicare Approves 24% Higher Payment for Oncocyte's Transplant Test: $1B Market Opportunity Expands - Stock Titan

May 19, 2025

May 19, 2025

Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology - The Globe and Mail

May 19, 2025

May 16, 2025

OncoCyte targets 20 transplant center milestone and upcoming FDA submission while advancing rebranding initiative - MSN

May 16, 2025

May 15, 2025

OncoCyte Corp’s Earnings Call: Optimism Amid Challenges - TipRanks

May 15, 2025

May 15, 2025

OncoCyte (NASDAQ:OCX) Earns “Buy” Rating from Needham & Company LLC - Defense World

May 15, 2025

May 14, 2025

OncoCyte (OCX) Seeks FDA Approval by 2026 - GuruFocus

May 14, 2025

May 14, 2025

OncoCyte Corporation (NASDAQ:OCX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025

May 13, 2025

Needham maintains Buy on OncoCyte, price target at $4.25 - Investing.com Australia

May 13, 2025

May 13, 2025

Needham maintains Buy on OncoCyte, price target at $4.25 By Investing.com - Investing.com Nigeria

May 13, 2025

May 13, 2025

OncoCyte Corp (OCX) Q1 2025 Earnings Call Highlights: Strategic Advances in Transplant Testing ... - Yahoo Finance

May 13, 2025

May 13, 2025

OncoCyte Corp (OCX) Q1 2025 Earnings Call Highlights: Strategic - GuruFocus

May 13, 2025

May 13, 2025

OncoCyte (OCX) Maintains 'Buy' Rating and Price Target by Needha - GuruFocus

May 13, 2025

May 12, 2025

Earnings call transcript: OncoCyte’s Q1 2025 revenue beats expectations By Investing.com - Investing.com Nigeria

May 12, 2025

May 12, 2025

OncoCyte Corp reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025

May 12, 2025

Earnings call transcript: OncoCyte’s Q1 2025 revenue beats expectations - Investing.com

May 12, 2025

May 12, 2025

OncoCyte: Q1 Earnings Snapshot - San Antonio Express-News

May 12, 2025

May 12, 2025

OncoCyte Corp (OCX) Q1 2025 Earnings: Revenue Soars to $2.1 Mill - GuruFocus

May 12, 2025

May 12, 2025

Oncocyte Reports Q1 2025 Results and Business Progress - The Manila Times

May 12, 2025

May 12, 2025

Oncocyte Corp. Reports Q1 2025 Revenue of $2.1 Million and Plans Company Renaming - Nasdaq

May 12, 2025

May 12, 2025

Oncocyte Corp SEC 10-Q Report - TradingView

May 12, 2025

May 08, 2025

Oncocyte to Release First Quarter 2025 Results on May 12, 2025 - The Manila Times

May 08, 2025

May 07, 2025

Oncocyte To Release First Quarter 2025 Results On May 12, 2025 - Barchart.com

May 07, 2025

May 06, 2025

Best Momentum Stocks to Buy for May 6th - The Globe and Mail

May 06, 2025

May 04, 2025

Geode Capital Management LLC Has $326,000 Stock Position in OncoCyte Co. (NASDAQ:OCX) - Defense World

May 04, 2025

Apr 30, 2025

Oncocyte Provides Positive Update on Clinical Trial Progress | O - GuruFocus

Apr 30, 2025

Apr 30, 2025

Why Tesla Stock Hit the Brakes Today - The Globe and Mail

Apr 30, 2025

Apr 30, 2025

AP PHOTOS: US stocks sink after a weak report on the economy - The Globe and Mail

Apr 30, 2025

Apr 30, 2025

Oncocyte (OCX) Advances Towards Crucial Clinical Trial for Trans - GuruFocus

Apr 30, 2025

Apr 30, 2025

Oncocyte advances toward clinical trial for transplant test By Investing.com - Investing.com India

Apr 30, 2025

Apr 30, 2025

Oncocyte advances toward clinical trial for transplant test - Investing.com Australia

Apr 30, 2025

Apr 30, 2025

Oncocyte Provides Positive Update on Clinical Trial Progress - The Manila Times

Apr 30, 2025

Apr 30, 2025

Oncocyte Provides Positive Update on Clinical Trial Progress | OCX Stock News - GuruFocus

Apr 30, 2025

Apr 30, 2025

Oncocyte Provides Positive Update On Clinical Trial ProgresS - marketscreener.com

Apr 30, 2025

Apr 30, 2025

Leading US Transplant Centers Back Oncocyte's Revolutionary Rejection Test Clinical Trial - Stock Titan

Apr 30, 2025

Apr 30, 2025

OncoCyte (NASDAQ:OCX) Trading Down 3.1% – Here’s What Happened - Defense World

Apr 30, 2025

Apr 29, 2025

Oncocyte study links blood test to kidney rejection markers - Investing.com

Apr 29, 2025

Apr 29, 2025

Economic Uncertainty Weighs on PayPal - The Globe and Mail

Apr 29, 2025

Apr 29, 2025

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Val - GuruFocus

Apr 29, 2025

Apr 29, 2025

Oncocyte (OCX) Unveils Promising Data on Transplant Rejection Te - GuruFocus

Apr 29, 2025